Published: May 21, 2021 By Alex Keown
Biopharma and life sciences companies strengthen their leadership teams and board with these Movers & Shakers.
AavantiBio – Jessie Hanrahan was named chief regulatory officer of AavantiBio. Hanrahan will oversee global regulatory affairs for AavantiBio’s diversified pipeline of gene therapy programs targeting rare diseases with significant unmet medical needs. Most recently, she was Vice President of Regulatory Science at bluebird bio, Inc. Prior to bluebird bio, Hanrahan held positions of increasing responsibility at Genzyme Corp. where she worked across the oncology, multiple sclerosis and rare disease therapeutic areas. Earlier in her career, Hanrahan worked at Boston Scientific Corporation.
Forbion Expands Team with New General Partner Tuesday, 18 May 2021 09:00 Hits: 862
NAARDEN, The Netherlands, May 18, 2021 / B3C newswire / Forbion, a leading European life sciences venture capital firm, is pleased to announce that Jasper Bos, PhD, a former Merck executive, has joined its growing investment team as General Partner for the firm’s Growth Fund. Before joining Forbion’s Naarden-based headquarters, Jasper was Senior Vice President and Managing Director at M Ventures, the venture arm of pharmaceutical giant Merck, which he joined in 2009. At M Ventures, he led a team of twenty-one investment professionals and with a fund size of €400 million invested in over 50 portfolio companies spanning biotech, life sciences tools, and tech companies with investment activities ranging from seed-stage to cross-over and IPO.